Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency

Summary

Mutations in the antithrombin (AT) gene can impair the capacity of AT to bind heparin (AT deficiency type IIHBS), its target proteases such as thrombin (type IIRS), or both (type IIPE). Type II AT deficiencies are almost exclusively caused by missense mutations, whereas type I AT deficiency can originate from missense or null mutations. In a retrospective cohort study, we investigated the impact of the type of mutation and type of AT deficiency on the manifestation of thromboembolic events in 377 patients with hereditary AT deficiencies (133 from our own cohort, 244 reported in the literature). Carriers of missense mutations showed a lower risk of venous thromboembolism (VTE) than those of null mutations (adjusted hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.27–0.58, p<0.001), and the risk of VTE was significantly decreased among patients with type IIHBS AT deficiency compared to patients with other types of AT deficiency (HR 0.23, 95%CI 0.13–0.41, p<0.001). The risk of pulmonary embolism complicating deep-vein thrombosis was lower in all type II AT deficiencies compared to type I AT deficiency (relative risk 0.69, 95%CI 0.56–0.84). By contrast, the risk of arterial thromboembolism tended to be higher in carriers of missense mutations than in those with null mutations (HR 6.08-fold, 95%CI 0.74–49.81, p=0.093) and was 5.9-fold increased (95%CI 1.22–28.62, p=0.028) in type IIHBS versus other types of AT deficiency. Our data indicate that the type of inherited AT defect modulates not only the risk of thromboembolism but also the localisation and encourage further studies to unravel this phenomenon.

Keywords

Antithrombin deficiency - SERPINC1 - mutation - venous thromboembolism - arterial thromboembolism

• References

• 1 Olds RJ, Lane DA, Mille BM. et al. Antithrombin: principal inhibitor of thrombin. Semin Thromb Hemost 1994; 20: 353-372.
• 2 Bedsted T, Swanson R, Chuang YJ. et al. Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry 2003; 42: 8143-8152.
• 3 Jin L, Abrahams JP, Skinner R. et al. The anticoagulant activation of antithrom-bin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
• 4 Johnson DJ, Li W, Adams TE. et al. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J 2006; 25: 2029-2037.
• 5 Ishiguro K, Kojima T, Kadomatsu K. et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
• 6 Bayton T, Lane D. Antithrombin Mutation Data Base. Departement of Haematology, Imperial College Faculty of Medicine, Charing Cross Hospital Campus London, UK.: 2003. Available at: http:/www1.imperial.ac.uk/departmentofmedi-cine/divisions/experimentalmedicine/haematology/coag/antithrombin. Last accessed November 2012.
• 7 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530.
• 8 Human Gene Mutation Database.. Available at: http://www.hgmd.cf.ac.uk/ac/index.php. Last accessed May 2012.
• 9 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
• 10 Lijfering WM, Brouwer JL, Veeger NJ. et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-5322.
• 11 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
• 12 De Stefano V, Leone G, Mastrangelo S. et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
• 13 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
• 14 Sanson BJ, Simioni P, Tormene D. et al. The incidence of venous thromboem-bolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94: 3702-3706.
• 15 Vossen CY, Conard J, Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-464.
• 16 Simioni P, Sanson BJ, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
• 17 Bucciarelli P, Rosendaal FR, Tripodi A. et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S defi- ciency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19: 1026-1033.
• 18 Rossi E, Ciminello A, Za T. et al. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost 2011; 106: 646-654.
• 19 Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003; 90: 17-26.
• 20 van Boven HH, Vandenbroucke JP, Briét E. et al. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited anti-thrombin deficiency. Blood 1999; 94: 2590-2594.
• 21 Tirado I, Mateo J, Soria JM. et al. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica 2001; 86: 1200-1208.
• 22 Mateo J, Oliver A, Borrell M. et al. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fi-brinolysis 1998; 9: 71-78.
• 23 Holzhauer S, Goldenberg NA, Junker R. et al. Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembol-ism: an observational study. Blood 2012; 120: 1510-1515.
• 24 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
• 25 Corral J, Hernandez-Espinosa D, Soria JM. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 26 Roldán V, Ordoñez A, Marín F. et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Hae-most 2009; 101: 483-486.
• 27 Pavlova A, El-Maarri O, Luxembourg B. et al. Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. Haematologica 2006; 91: 1264-1267.
• 28 Martínez-Martínez I, Johnson DJ, Yamasaki M. et al. Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance. J Thromb Haemost 2012; 10: 1859-1866.
• 29 Raja SM, Chhablani N, Swanson R. et al. Deletion of P1 arginine in a novel anti-thrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J Biol Chem 2003; 278: 13688-13695.
• 30 Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001; 115: 491-506.
• 31 Mahmoodi BK, Brouwer JL, Veeger NJ. et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-1667.
• 32 Kuhle S, Lane DA, Jochmanns K. et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001; 86: 1007-1011.
• 33 Szilágyi S, Péter A, Magyar MT. et al. Recurrent arterial thrombosis associated with the antithrombin basel variant and elevated lipoprotein(a) plasma level in an adolescent patient. J Pediatr Hematol Oncol 2012; 34: 276-279.
• 34 Shimizu K, Toriyama F, Ogawa F. et al. Recurrent leg ulcers and arterial thrombosis in a 33-year-old homozygous variant of antithrombin. Am J Hematol 2001; 66: 285-291.
• 35 Rossi E, Za T, Ciminello A. et al. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost 2008; 99: 1030-1034.
• 36 Talbot K, Meixner SC, Pryzdial EL. Proteolytic modulation of factor Xa-anti-thrombin complex enhances fibrinolysis in plasma. Biochim Biophys Acta 2013; 1834: 989-995.
• 37 Dudani AK. Plasminogen and tissue plasminogen activator interact with anti-thrombin III. Thromb Res. 2000; 99: 635-641.
• 38 Lane DA, Olds RJ, Conard J. et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433.